SOURCES SOUGHT
A -- Medication Measures for Part D
- Notice Date
- 6/10/2005
- Notice Type
- Sources Sought
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, Centers for Medicare & Medicaid Services, formerly known as the Health Care Financing Administration, Acquisition and Grants Group, 7500 Security Blvd. C2-21-15, Central Building, Baltimore, MD, 21244-1850
- ZIP Code
- 21244-1850
- Solicitation Number
- Reference-Number-CMS-05-MM-LMG
- Response Due
- 6/22/2005
- Archive Date
- 7/7/2005
- Description
- This notice is published for the purposes of conducting market research. The Centers for Medicare and Medicaid Services (CMS) is seeking to identify Small Business, Small Disadvantaged Businesses, Hub-Zone Small Businesses, Service-Disabled Veteran-Owned Small Businesses, Woman-Owned Small Businesses to develop Part D Medication measures at the Prescription Drug Plans (PDPs) and/or Medicare Advantage Prescription Drug Plans (MA-PDPs), pharmacy and/or physician level that can be used for quality improvement and intervention, evaluation and monitoring of the clinical and economic impact of the Part D benefit, and for public reporting purposes. The measures (to the extent feasible) shall be based on the Institute of Medicine?s (IOMs) domains of safety, effectiveness, patient-centered, timeliness, efficiency and equitability. A limited number of measures shall be developed that focus on specific categories/subcategories. The measures shall be limited to approximately two specific disease states and up to 10 specific drugs or drug classes. The categories/subcategories are: 1. Prescribing?Use of avoidable drugs in elderly; Generic prescribing ratios; Use of selected medications within certain therapeutic categories; 2. Disease-specific therapy?Drug-disease interactions; Therapeutic monitoring associated with specific drug utilization; 3. Appropriateness of Therapy Measures--appropriate prescribing and drug regimen for specified disease states such as: Cardiovascular (Heart Failure, Coronary Artery Disease/Acute Myocardial Infarction, Artial Fibrillation, and Hypertension); Second disease state will be determined by CMS 4. Cost effective drug utilization management/economic impact; 5. Quality assurance to reduce medication errors and adverse drug interactions and improve medication use; and 6. Controlling fraud, abuse and waste. Interested sources must possess an existing license and expertise in the use of Medispan, First Data Bank or other comparable system. Comparable systems shall meet the following mandatory criteria: The system shall (a) identify and monitor all active drug ingredients in single and combination products for all prescription medications based on National Drug Code (NDC) with the capability of being readily updated (at least monthly); (b) identify and monitor all Level 1 and Level 2 drug-drug interactions based on NDC comparisons. Level 1 and Level 2 drug-drug interactions shall be defined as outlined in the review process conducted by ?Taro DS, ed. Drug Interaction Facts. St. Louis, MO: Facts and Comparisons: 2002;? (c) identify and monitor High Severity and Low Severity drug-disease interactions based on NDC to ICD-9 Code comparisons; and through the use of medications that are indicative of a given illness. High Severity and Low Severity drug-disease interactions shall be defined as outlined in the review process conducted by ?Beers MH. Explicit Criteria for Determining Potentially Inappropriate Medication by the Elderly: An Update. Arch Intern Med. 1997; 157-:1531-1536;? (d) identify and monitor all therapeutic duplications for therapeutic class duplication based on NDC; and (f) organize, identify and monitor all prescription medications by the therapeutic use classifications of Drug Category, Drug Group, and Drug Class based on NDC; and provide medication acquisition costs. The period of performance to complete this work is 12 months. Qualified sources may submit a capability statement that will be considered by CMS. The capability statement must demonstrate that the firm has the capability to perform the work, experience in measure development work, working with the health care community and proof of current appropriate license for Medispan or First Data Bank that will be valid for the 12 months. If an interested source has a comparable system they must submit proof that the system meets the above mandated requirements. Sources shall clearly demonstrate their experience and proficiency with an active and on-going program using Medispan, First Data Bank or other comparable system. The capability statement shall include references (appropriate information for former employers, current suppliers, vendors, and other external business contacts). CMS reserves the right to contact the references to substantiate that firm has an active and on-going program using Medispan, First Data Bank or other comparable system. Interested sources are advised that this synopsis is for informational purposes only and does not constitute a Request for Proposal or other commitment by CMS. The capability statements are limited to 15 pages or less will be evaluated to identify qualified potential sources. Responses to this market research must be submitted prior to 3 p.m. local prevailing time on June 22, 2005. Organizations must specify a point of contact, telephone number and indicate their size status under North American Industry Classification System (NAICS) Code 541710, see FAR 19.102. Interested sources should submit appropriate documentation on their capability and qualifications to perform this effort to CMS, Attn: Linda Gmeiner, Contract Specialist, 7500 Security Blvd., M/S C2-21-15, Baltimore, MD 21244. CMS will not pay for any information submitted.
- Record
- SN00827378-W 20050612/050612190234 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |